Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Rhea-AI Summary

Immunic, Inc. (IMUX) announced hosting a Multiple Sclerosis (MS) Research and Development Day and participation in investor conferences. The company's management will discuss the latest developments in the MS landscape and present clinical data on their late-stage clinical asset, vidofludimus calcium.

NEW YORK, April 4, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following investor conferences in April:

• April 9: Immunic's MS R&D Day. Management of Immunic, including Daniel Vitt, Ph.D., Chief Executive Officer and President, Andreas Muehler, M.D., M.B.A. Chief Medical Officer and Hella Kohlhof, Ph.D, Chief Scientific Officer, will be joined by renowned key opinion leaders to discuss the latest developments in the MS landscape as well as recent preclinical and clinical data supporting the neuroprotective potential of Immunic's late-stage clinical asset, first-in-class Nurr1 activator, vidofludimus calcium. The MS R&D Day will take place on Tuesday, April 9, 2024, from 10:30 am to 12:30 pm PST in-person at the Hotel Nikko in San Francisco. To register, please RSVP by sending an email to: ir@imux.com.
• April 15-17: Accelerating Bio-Innovation 2024 UK. Dr. Vitt will participate in one-on-one meetings at this conference in Cambridge, England.
• April 17-18: Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference. Dr. Vitt will participate in a fireside chat and one-on-one investor meetings at this virtual conference. A webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations. An archived replay will be available after the conference.

About Immunic, Inc. 
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, for which it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements 
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in corporate events and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 22, 2024, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
kaplan@kogspr.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-host-ms-rd-day-and-participate-in-investor-conferences-in-april-302107242.html

SOURCE Immunic, Inc.

FAQ

When will Immunic host the MS R&D Day?

Immunic will host the MS R&D Day on Tuesday, April 9, 2024, from 10:30 am to 12:30 pm PST in-person at the Hotel Nikko in San Francisco.

What is the late-stage clinical asset discussed at the MS R&D Day?

The late-stage clinical asset discussed is the first-in-class Nurr1 activator, vidofludimus calcium.

Where can investors watch the webcast of the presentation at the Noble Capital Markets conference?

Investors can watch the webcast of the presentation at the Noble Capital Markets conference on the 'Events and Presentations' section of Immunic's website at: https://ir.imux.com/events-and-presentations.